[HTML][HTML] Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus
S Chou, RJ Ercolani, K Derakhchan - Antiviral research, 2018 - Elsevier
The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical
trials as antiviral therapy, including use for infections refractory or resistant to standard …
trials as antiviral therapy, including use for infections refractory or resistant to standard …
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
WL Drew, RC Miner, GI Marousek, S Chou - Journal of clinical virology, 2006 - Elsevier
BACKGROUND: The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
undergoing clinical antiviral trials. OBJECTIVES: To assess the MBV sensitivity of CMV …
Maribavir: a novel antiviral agent with activity against cytomegalovirus
J Trofe, L Pote, E Wade, E Blumberg… - Annals of …, 2008 - journals.sagepub.com
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of maribavir,
a novel antiviral agent in the benzimidazole drug class. Data sources: Articles were …
a novel antiviral agent in the benzimidazole drug class. Data sources: Articles were …
Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
RG Gandhi, CN Kotton - Therapeutics and Clinical Risk …, 2022 - Taylor & Francis
Purpose of Review Cytomegalovirus (CMV) infections are a common complication in solid
organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased …
organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased …
Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus
S Chou, GI Marousek - Antimicrobial agents and chemotherapy, 2006 - Am Soc Microbiol
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir antagonized the anti-CMV
effect of ganciclovir, increasing the ganciclovir 50% inhibitory concentration against a …
effect of ganciclovir, increasing the ganciclovir 50% inhibitory concentration against a …
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
S Chou, M Hakki, S Villano - Antiviral research, 2012 - Elsevier
Resistance to the experimental human cytomegalovirus (CMV) UL97 kinase inhibitor
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
maribavir has been mapped to UL97 mutations at codons 353, 397, 409 and 411, in the …
Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections
P Frange, M Leruez-Ville - Medecine et maladies infectieuses, 2018 - Elsevier
Cytomegalovirus (CMV) infection is a common complication in immunocompromised
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic …
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic …
[HTML][HTML] Maribavir for preemptive treatment of cytomegalovirus reactivation
J Maertens, C Cordonnier, P Jaksch… - … England Journal of …, 2019 - Mass Medical Soc
Background Maribavir is a benzimidazole riboside with activity against cytomegalovirus
(CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in …
(CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in …
Maribavir: first approval
C Kang - Drugs, 2022 - Springer
Abstract Maribavir (LIVTENCITYTM), a cytomegalovirus (CMV) enzyme pUL97 kinase
inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections …
inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections …
Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection
S Chou, K Song, J Wu, T Bo… - The Journal of infectious …, 2022 - academic.oup.com
Background In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …
(CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for …